RSV Vaccine

Moore, M

Meissa Therapeutics, a faculty startup by Emory Professor Martin Moore, develops vaccines targeted at respiratory viruses. The RSV vaccine will prevent Respiratory Syncytial Virus, one of the largest unmet respiratory needs in pediatrics. Meissa’s pre-clinical lead, MV-012-968, employs the Emory-developed synthetic biology and reverse genetics to recode non-essential RSV genes using codon deoptimization.